INNATE PHARMA SA-SPONS ADR (IPHA) Stock Price, Quote, News and Overview

Company Profile

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. The company is headquartered in Marseille, Paca and currently employs 168 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.

Company Info

INNATE PHARMA SA-SPONS ADR

117 avenue de Luminy, Bp 30191

Marseille PACA 13009 FR

CEO: Mondher Mahjoubi

Employees: 168

Company Website: https://www.innate-pharma.com/

Investor Relations: https://investors.innate-pharma.com

Phone: 33430303030